Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio

Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024.

Word of the acquisition was first shared by Oxular’s former CEO and board member Mark Gaffney, who now helms Calluna Pharma.